MFIMFI
PCRX icon

Mesirow Financial Investment Management - Fixed Income’s Pacira BioSciences PCRX Stock Holding History

Mesirow Financial Investment Management - Fixed Income’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-140,927
Closed -$8.22M – 76
2022
Q2 		$8.22M Sell
140,927
-67,270
-32% -$4.41M 1.05% 43
2022
Q1 		$15.9M Sell
208,197
-45
-0% -$3K 1.76% 6
2021
Q4 		$12.5M Sell
208,242
-2,635
-1% -$145K 1.38% 13
2021
Q3 		$11.8M Sell
210,877
-1,235
-0.6% -$71.2K 1.37% 13
2021
Q2 		$12.9M Buy
212,112
+91,880
+76% +$5.82M 1.44% 6
2021
Q1 		$8.43M Sell
120,232
-23,995
-17% -$1.71M 0.98% 47
2020
Q4 		$8.63M Buy
144,227
+15,725
+12% +$921K 1.16% 23
2020
Q3 		$7.73M Buy
128,502
+2,845
+2% +$165K 1.31% 11
2020
Q2 		$6.59M Sell
125,657
-24,335
-16% -$1.02M 1.2% 22
2020
Q1 		$5.03M Buy
149,992
+47,581
+46% +$1.98M 1.2% 35
2019
Q4 		$4.64M Sell
102,411
-19,055
-16% -$809K 0.72% 81
2019
Q3 		$4.62M Buy
121,466
+11,855
+11% +$473K 0.77% 77
2019
Q2 		$4.77M Buy
109,611
+19,690
+22% +$836K 0.74% 74
2019
Q1 		$3.42M Sell
89,921
-64,815
-42% -$2.53M 0.53% 75
2018
Q4 		$6.66M Sell
154,736
-31,170
-17% -$1.45M 0.9% 71
2018
Q3 		$9.14M Sell
185,906
-53,735
-22% -$2.32M 0.83% 75
2018
Q2 		$7.68M Sell
239,641
-67,145
-22% -$2.32M 0.71% 76
2018
Q1 		$9.55M Sell
306,786
-103,775
-25% -$3.69M 0.94% 68
2017
Q4 		$18.7M Buy
410,561
+19,876
+5% +$788K 1.32% 29
2017
Q3 		$14.7M Buy
+390,685
New +$15.7M 0.97% 70

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Mesirow Financial Investment Management - Fixed Income's PCRX Position: Q3 2022 in Review

Mesirow Financial Investment Management - Fixed Income sold out of Pacira BioSciences (PCRX) in Q3 2022, closing a stake of 140,927 shares — an estimated $8.22M sold.

Mesirow Financial Investment Management - Fixed Income first reported a position in PCRX in Q3 2017 and held it in 20 quarters. The position peaked at $18.7M in Q4 2017. 273 funds tracked by Wall St. Rank hold PCRX as of Q3 2022.

  • Mesirow Financial Investment Management - Fixed Income reported no remaining Pacira BioSciences position as of Q3 2022 after selling out during the quarter.
  • Mesirow Financial Investment Management - Fixed Income sold 140,927 Pacira BioSciences shares in Q3 2022, an estimated $8.22M.
  • Mesirow Financial Investment Management - Fixed Income first reported a position in Pacira BioSciences in Q3 2017 and held it in 20 quarters.
  • Mesirow Financial Investment Management - Fixed Income's Pacira BioSciences position peaked at $18.7M in Q4 2017.
  • 273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2022.

Based on Mesirow Financial Investment Management - Fixed Income's 13F filing for Q3 2022, filed 8 Nov 2022.